An Integrative Review of the Prevalence of Depression among Pediatric Patients with Sickle Cell Disease

Moody, Kendall L; Mercer, Kimberley; Glass, Mitzi

doi:10.1080/19371918.2019.1606754

Cited by 15 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Depression and anxiety are diagnosable disorders that cause a persistent feeling of sadness and loss of interest, or a feeling of unease, such as worry or fear, respectively. The prevalence of depression in the pediatric SCD population is unclear, with estimates between 4 and 46% ( 84 ). These estimates are mostly much higher than the general population of Non-Hispanic Black adolescents and young adults (7–9%) ( 85 ).…”

Section: Selecting Cognitive and Psychological Domainsmentioning

confidence: 99%

Considerations for Selecting Cognitive Endpoints and Psychological Patient-Reported Outcomes for Clinical Trials in Pediatric Patients With Sickle Cell Disease

et al. 2022

View full text Add to dashboard Cite

Pediatric patients with sickle cell disease (SCD) experience a range of medical complications that result in significant morbidity and mortality. Recent advances in prophylactic and curative treatment approaches have highlighted the need for sensitive and clinically-meaningful trial endpoints. The detrimental effects of cognitive and psychological difficulties on social and economic mobility are well described. Although numerous reviews have assessed cognitive outcomes in other rare genetic disorders, SCD has not received the same focus. This review describes the cognitive (i.e., executive function and processing speed) and psychological domains (i.e., depression and anxiety) that are consistently associated with SCD pathology and, therefore, may be of particular interest as clinical trial endpoints. We then discuss corresponding well-validated and reliable cognitive tests and patient-reported outcomes (PROs) that may be appropriate for clinical trials given their robust psychometric properties, ease of administration, and previous use in the SCD population. Further, we provide a discussion of potential pitfalls and considerations to guide endpoint selection. In line with the move toward patient-centered medicine, we identify specific tests (e.g., NIH Toolbox Cognition Module, Wechsler Cancellation Test) and psychological PROs (e.g., PROMIS depression and anxiety scales) that are sensitive to SCD morbidity and have the potential to capture changes that are clinically meaningful in the context of patients' day to day lives. In particularly vulnerable cognitive domains, such as executive function, we highlight the advantages of composite over single-test scores within the context of trials. We also identify general (i.e., practice effects, disease heterogeneity) and SCD-specific considerations (i.e., genotype, treatment course, and disease course, including degree of neurologic, pain, and sleep morbidity) for trial measures. Executive function composites hold particular promise as trial endpoints that are clinically meaningful, amenable to change, relatively easy to collect, and can be incorporated into the routine care of patients with SCD in various settings and countries.

show abstract

Section: Selecting Cognitive and Psychological Domainsmentioning

confidence: 99%

Considerations for Selecting Cognitive Endpoints and Psychological Patient-Reported Outcomes for Clinical Trials in Pediatric Patients With Sickle Cell Disease

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Nevertheless, effective engagement in self-management is one key pathway to optimising both medication adherence and clinical outcomes, so as to reduce or minimise avoidable healthcare utilisation and costs (Cronin 2019;Modi 2012). Moreover, with the increasing prevalence of chronic pain (Dampier 2017), opioid overexposure (Ballas 2018;Han 2018;Sinha 2019;Telfer 2014) and psychological distress, particularly depression, among people with SCD (Moody 2019;Pecker 2019), there has been growing need for digital interventions that deliver non-pharmacological treatment, such as cognitive behavioural therapy focused on coping skills training and psychosocial support.…”

Section: Why It Is Important To Do This Reviewmentioning

confidence: 99%

Digital behavioural interventions for people with sickle cell disease

Badawy

Cronin

Liem

et al. 2021

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:To identify and assess the effects of digital behavioural interventions focused on behavioural change in people with SCD on: •medication adherence or disease management (such as managing acute and chronic pain), or both, on health-and other-related outcomes;• specific subgroups defined by age (i.e. children, adolescents and adults) and type of modality or delivery (e.g. cell phone, the Internet). BACKGROUND Description of the conditionSickle cell disease (SCD) is an inherited haemoglobin disorder affecting more than five million individuals globally; and annually affecting 250,000 to 300,000 live births worldwide (Piel 2013; Piel 2017). It is important to note that both prevalence and incidence are estimates and given that newborn screening does not exist in many countries, these numbers are likely underestimating the global burden of SCD. In the USA, SCD is

show abstract

“…However, clinicians often fail to recognize the presence of depression. The prevalence of depression in SCD ranged from 4%-46% according to a systematic review carried out in the US [14]. In sickle cell disease, depression is associated with pain, poor treatment compliance and lower quality of life [15].…”

Section: Introductionmentioning

confidence: 99%

Burden of Depression and Associated Factors among Patients with Sickle Cell Disease in Fako Division, Cameroon

Monono

2023

JPAR

View full text Add to dashboard Cite

Background: Depression is a major public health challenge causing significant suffering and disability worldwide. Patients with Sickle Cell Disease (SCD) suffer from various complications during their lifetime and are prone to depression. However, there is a paucity of information on depression and associated factors among sickle cell patients in Cameroon. Objectives: To determine the prevalence of depression and associated factors among patients with SCD aged 7-40 years receiving care in three hospitals in Fako Division. Methods: We carried out a hospital based cross-sectional descriptive and analytic study. Socio-demographic data, clinical variables and depressive symptoms were evaluated using a structured questionnaire. Depression was evaluated using the Patient Health Questionnaire Module 9 and the Children’s Depression Inventory. The Statistical Package for Social Sciences (SPSS) version 25 was used for analysis of data. Statistical significance was set at p value <0.05 while bivariate and multivariate analysis was used to test for associations. Results: We recruited 163 participants and the prevalence of depression was 43%(n=70), of which 30.67%(n=50) were mildly depressed and 12.27%(n=20) were moderately depressed. The prevalence of suicidal ideation was 20%. On multivariate analysis, an unmarried status (AOR 7.41; 95%CI 1.74-31.54, P<0.007) high pain intensity (AOR 8.70; 95%CI 17.77-42.82, P<0.008) and history of painful crises within the previous month (AOR 7.31,95%CI 1.52-35.14, P<0.013) were associated with depression among these patients. Conclusion: Almost half of our patients with SCD are depressed, with 2 of them out of 10 thinking of suicide. Some socio-demographic and clinical factors induce this depressive state.

show abstract

An Integrative Review of the Prevalence of Depression among Pediatric Patients with Sickle Cell Disease

Cited by 15 publications

References 29 publications

Considerations for Selecting Cognitive Endpoints and Psychological Patient-Reported Outcomes for Clinical Trials in Pediatric Patients With Sickle Cell Disease

Considerations for Selecting Cognitive Endpoints and Psychological Patient-Reported Outcomes for Clinical Trials in Pediatric Patients With Sickle Cell Disease

Digital behavioural interventions for people with sickle cell disease

Burden of Depression and Associated Factors among Patients with Sickle Cell Disease in Fako Division, Cameroon

Contact Info

Product

Resources

About